NCT01140737 - A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 11, 2016

Study Completion Date

January 8, 2019

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

Axitinib

Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.

Trial Locations (13)

Unknown

Aberdeen Royal Infirmary, Aberdeen

Western General Hospital, Edinburgh

Bristol Haematology & Oncology Centre, Bristol

St. James's Hospital, Leeds

Royal Marsden Hospital, London

Royal Marsden, London

University College London Hospitals, London

Christies, Manchester

Clatterbridge Centre for Oncology, Metropolitan Borough of Wirral

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Penella Woll, Sheffield

Southampton General Hospital, Southampton